An updated patent review on ocular drug delivery systems with potential for commercial viability
- PMID: 21453249
- DOI: 10.2174/187221111795471436
An updated patent review on ocular drug delivery systems with potential for commercial viability
Abstract
The eye due to its special attributes is an effortlessly accessible location for topical drug administration. Topical administration not only provides local targeting of drugs but also offers a better control over the systemic delivery. Bioavailability of drugs from ocular dosage forms is dependent to the precorneal loss factors (physiological and anatomical constraints of eye) thus, very small fraction of the drug is absorbed through ocular route. The effective dose of medication administered ophthalmically may be altered by changing the formulation. Various research reports have been documented for ocular drug delivery, both on academic level as well as commercial level resulting in augmented increase in the numbers of patents in this field. The primary objective of the present review is to provide an overview of the ocular drug delivery systems with special emphasis on the intellectual aspects of these systems. This paper also attempts to extend the information on ocular drug delivery systems already existing in the literature by focusing on the update on the patents granted as well as applications published for these systems during the last decade.
Similar articles
-
Recent patents on ocular drug delivery systems.Recent Pat Drug Deliv Formul. 2008;2(1):1-8. doi: 10.2174/187221108783331410. Recent Pat Drug Deliv Formul. 2008. PMID: 19075892 Review.
-
Recent patents and advances in ophthalmic drug delivery.Recent Pat Drug Deliv Formul. 2007;1(2):161-70. doi: 10.2174/187221107780831923. Recent Pat Drug Deliv Formul. 2007. PMID: 19075883 Review.
-
Patent perspectives for corticosteroids based ophthalmic therapeutics.Recent Pat Drug Deliv Formul. 2014;8(3):206-23. doi: 10.2174/1872211308666140713171702. Recent Pat Drug Deliv Formul. 2014. PMID: 25020063 Review.
-
Advances in ocular drug delivery.Curr Eye Res. 2012 May;37(5):345-56. doi: 10.3109/02713683.2011.652286. Curr Eye Res. 2012. PMID: 22510004 Review.
-
Ocular preparations: the formulation approach.Drug Dev Ind Pharm. 2002 May;28(5):473-93. doi: 10.1081/ddc-120003445. Drug Dev Ind Pharm. 2002. PMID: 12098838 Review.
Cited by
-
Successfully improving ocular drug delivery using the cationic nanoemulsion, novasorb.J Drug Deliv. 2012;2012:604204. doi: 10.1155/2012/604204. Epub 2012 Feb 27. J Drug Deliv. 2012. PMID: 22506123 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical